{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:16:47Z","timestamp":1761920207504,"version":"build-2065373602"},"reference-count":140,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2423,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s13311-016-0486-7","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T09:56:18Z","timestamp":1476784578000},"page":"135-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases"],"prefix":"10.1016","volume":"14","author":[{"given":"Nabil K.","family":"El Ayoubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0486-7_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2009.09.002","article-title":"Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis","volume":"219","author":"Awad","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1007\/s13311-016-0486-7_bib4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.0b013e3181c97c8f","article-title":"Multiple sclerosis immunology: the healthy immune system vs the MS immune system","volume":"74","author":"Kasper","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.autrev.2011.05.006","article-title":"A clear look at the neuroimmunology of multiple sclerosis and beyond","volume":"11","author":"Selmi","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-016-0486-7_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/ard.2008.098020","article-title":"Lessons from multiple sclerosis: models, concepts, observations","volume":"67","author":"Wekerle","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-016-0486-7_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s004410000179","article-title":"Apoptosis in multiple sclerosis","volume":"301","author":"Zipp","year":"2000","journal-title":"Cell Tissue Res"},{"key":"10.1007\/s13311-016-0486-7_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jneuroim.2007.09.015","article-title":"Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system","volume":"191","author":"Pender","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"10.1007\/s13311-016-0486-7_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5692\/clinicalneurol.49.715","article-title":"Clinical and pathological topics of multiple sclerosis","volume":"49","author":"Lassmann","year":"2009","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1007\/s13311-016-0486-7_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.expneurol.2009.10.009","article-title":"Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models","volume":"225","author":"Lassmann","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1471-4914(00)01909-2","article-title":"Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy","volume":"7","author":"Lassmann","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1007\/s13311-016-0486-7_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-016-0486-7_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib17","first-page":"117","article-title":"Stratification and monitoring of Natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0486-7_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-016-0486-7_bib19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/awh176","article-title":"Development of biomarkers in multiple sclerosis","volume":"127","author":"Bielekova","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-016-0486-7_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2009.04.010","article-title":"Cerebrospinal fluid biomarkers in multiple sclerosis","volume":"35","author":"Tumani","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-016-0486-7_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF03256329","article-title":"Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making","volume":"13","author":"Harris","year":"2009","journal-title":"Mol Diagn Ther"},{"key":"10.1007\/s13311-016-0486-7_bib22","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib23","doi-asserted-by":"crossref","first-page":"e0128952","DOI":"10.1371\/journal.pone.0128952","article-title":"Plasma biomarkers discriminate clinical forms of multiple sclerosis","volume":"10","author":"Tejera-Alhambra","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-016-0486-7_bib24","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1177\/1352458513485654","article-title":"Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis","volume":"19","author":"Fenoglio","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib25","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.4049\/jimmunol.1201516","article-title":"NLRP3 inflammasome activity is negatively controlled by miR-223","volume":"189","author":"Bauernfeind","year":"2012","journal-title":"J Immunol"},{"key":"10.1007\/s13311-016-0486-7_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15252\/embr.201438923","article-title":"MicroRNA-15b promotes neurogenesis and inhibits neural progenitor proliferation by directly repressing TET3 during early neocortical development","volume":"15","author":"Lv","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1007\/s13311-016-0486-7_bib27","doi-asserted-by":"crossref","first-page":"e12132","DOI":"10.1371\/journal.pone.0012132","article-title":"MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood","volume":"5","author":"Cox","year":"2010","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-016-0486-7_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1352458513496343","article-title":"Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing","volume":"20","author":"Keller","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib29","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1007\/s11033-011-1441-7","article-title":"Circulating microRNAs involved in multiple sclerosis","volume":"39","author":"Siegel","year":"2012","journal-title":"Mol Biol Rep"},{"key":"10.1007\/s13311-016-0486-7_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med"},{"key":"10.1007\/s13311-016-0486-7_bib31","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1007\/s13311-016-0486-7_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2014.03.001","article-title":"Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system","volume":"270","author":"Tanaka","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib34","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib35","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1073\/pnas.0806310105","article-title":"Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis","volume":"105","author":"Quintana","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-016-0486-7_bib36","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1212\/WNL.0000000000001066","article-title":"Epitope spreading as an early pathogenic event in pediatric multiple sclerosis","volume":"83","author":"Quintana","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","article-title":"Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis","volume":"64","author":"Lycke","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0486-7_bib38","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestrom","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1352458507082061","article-title":"Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis","volume":"14","author":"Rejdak","year":"2008","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib40","first-page":"126","article-title":"Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome","volume":"87","author":"Disanto","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0486-7_bib41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000008181","article-title":"Increased cerebrospinal fluid tau protein in multiple sclerosis","volume":"43","author":"Kapaki","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00415-004-0336-0","article-title":"Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG","volume":"251","author":"Bartosik-Psujek","year":"2004","journal-title":"J Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neulet.2004.03.039","article-title":"Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis","volume":"363","author":"Martinez-Yelamos","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-016-0486-7_bib44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00702-005-0327-z","article-title":"The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis","volume":"113","author":"Bartosik-Psujek","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1007\/s13311-016-0486-7_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1191\/1352458506ms1288sr","article-title":"Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis","volume":"12","author":"Guimaraes","year":"2006","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0404.2007.00782.x","article-title":"Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis","volume":"115","author":"Terzi","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-016-0486-7_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1191\/1352458505ms1159oa","article-title":"Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis","volume":"11","author":"Brettschneider","year":"2005","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa1110740","article-title":"Potassium channel KIR4.1 as an immune target in multiple sclerosis","volume":"367","author":"Srivastava","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0486-7_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1212\/WNL.0000000000000097","article-title":"Potassium channel KIR4.1- specific antibodies in children with acquired demyelinating CNS disease","volume":"82","author":"Kraus","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib50","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1177\/1352458514531086","article-title":"Lack of confirmation of antiinward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis","volume":"20","author":"Nerrant","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(14)70141-3","article-title":"Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study","volume":"13","author":"Brickshawana","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib52","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/1352458514551779","article-title":"Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?","volume":"21","author":"Brill","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-3940(02)00887-X","article-title":"Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis","volume":"331","author":"Leoni","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-016-0486-7_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3940(03)00667-0","article-title":"Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients","volume":"347","author":"Teunissen","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-016-0486-7_bib55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1352458513499421","article-title":"Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis","volume":"20","author":"Van de Kraats","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0486-7_bib57","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"MOG cell-based assay detects Non-MS Patients with inflammatory neurologic disease. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib58","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/brain\/awv017","article-title":"Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes","volume":"138","author":"Cant\u00f3","year":"2015","journal-title":"Brain"},{"key":"10.1007\/s13311-016-0486-7_bib59","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/1352458514561906","article-title":"Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis","volume":"21","author":"Hinsinger","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0404.2006.00749.x","article-title":"Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies","volume":"115","author":"Szczucinski","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-016-0486-7_bib61","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/1352458509107017","article-title":"Serum levels of CXCL13 are elevated in active multiple sclerosis","volume":"15","author":"Festa","year":"2009","journal-title":"Mult. Scler"},{"key":"10.1007\/s13311-016-0486-7_bib62","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0b013e3181c5b457","article-title":"Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS","volume":"73","author":"Sellebjerg","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib63","doi-asserted-by":"crossref","first-page":"e11986","DOI":"10.1371\/journal.pone.0011986","article-title":"The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)","volume":"5","author":"Brettschneider","year":"2010","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-016-0486-7_bib64","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458511398887","article-title":"Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid","volume":"17","author":"Ragheb","year":"2011","journal-title":"Mult Scler"},{"doi-asserted-by":"crossref","unstructured":"Martinelli V, Dalla CG, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014; 20:147\u2013155.","key":"10.1007\/s13311-016-0486-7_bib66","DOI":"10.1177\/1352458513494959"},{"key":"10.1007\/s13311-016-0486-7_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneuroim.2011.02.009","article-title":"Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and mri follow-up study","volume":"234","author":"Hagman","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0165-5728(01)00455-6","article-title":"Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability","volume":"122","author":"Semra","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0022-510X(99)00178-1","article-title":"Axonal degeneration in the pathogenesis of multiple sclerosis","volume":"170","author":"Silber","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-016-0486-7_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/01.WNL.0000041496.58127.E3","article-title":"Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy","volume":"60","author":"Eikelenboom","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/1352458504ms1100oa","article-title":"Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis","volume":"10","author":"Ehling","year":"2004","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib72","doi-asserted-by":"crossref","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-016-0486-7_bib73","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1352458512458010","article-title":"CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome","volume":"19","author":"Khalil","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib75","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1007\/s00415-014-7507-4","article-title":"N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis","volume":"261","author":"Trentini","year":"2014","journal-title":"J Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib76","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1007\/s13311-016-0486-7_bib77","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jnnp-2013-307454","article-title":"Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome","volume":"86","author":"Kuhle","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0486-7_bib78","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/brain\/awq035","article-title":"Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis","volume":"133","author":"Comabella","year":"2010","journal-title":"Brain"},{"key":"10.1007\/s13311-016-0486-7_bib79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-5728(00)00310-6","article-title":"Increased cellular expression of the caspase inhibitor FLIP in intrathecal lymphocytes from patients with multiple sclerosis","volume":"111","author":"Sharief","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib80","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0165-5728(00)00443-4","article-title":"Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis","volume":"113","author":"Semra","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib81","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1468-1331.2002.00454.x","article-title":"Upregulated surviving expression in activated T lymphocytes correlates with disease activity in multiple sclerosis","volume":"9","author":"Sharief","year":"2002","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0165-5728(97)00012-X","article-title":"Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy","volume":"75","author":"Inoue","year":"1997","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib83","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.55.7.928","article-title":"Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS","volume":"55","author":"Huang","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib84","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1034\/j.1600-0404.2003.00002.x","article-title":"Fas expression on T cells and sFas in relapsing-remitting multiple sclerosis","volume":"107","author":"Bilinska","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-016-0486-7_bib85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0165-5728(02)00437-X","article-title":"Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis","volume":"135","author":"Gomes","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clineuro.2004.02.020","article-title":"Level of sFas\/APO 1 in serum and cerebrospinal fluid in multiple sclerosis","volume":"106","author":"Mahovic","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-016-0486-7_bib87","first-page":"220","article-title":"The Blood\u2013brain barrier, chemokines and multiple sclerosis","volume":"2011","author":"Holman","year":"1812","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-016-0486-7_bib88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneuroim.2005.06.019","article-title":"Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis","volume":"167","author":"Kuenz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib89","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/brain\/122.2.191","article-title":"Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study","volume":"122","author":"Lee","year":"1999","journal-title":"Brain"},{"key":"10.1007\/s13311-016-0486-7_bib90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1212\/WNL.60.1.52","article-title":"IFN beta lowers MMP-9\/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS","volume":"60","author":"Waubant","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib91","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00415-003-1041-0","article-title":"Nitric oxide as an activity marker in multiple sclerosis","volume":"250","author":"Acar","year":"2003","journal-title":"J Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib92","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/01.WNL.0000142043.32578.5D","article-title":"CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis","volume":"63","author":"Rejdak","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib93","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jnr.10408","article-title":"Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels","volume":"70","author":"Calabrese","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-016-0486-7_bib94","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jns.2007.03.012","article-title":"Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis?","volume":"265","author":"Hohlfeld","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-016-0486-7_bib95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","article-title":"Lower brain derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate","volume":"167","author":"Azoulay","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib96","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neulet.2009.05.057","article-title":"Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse","volume":"460","author":"Frota","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-016-0486-7_bib97","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2007.06.003","article-title":"Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis","volume":"188","author":"Weinstock-Guttman","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib98","doi-asserted-by":"crossref","first-page":"153ra131","DOI":"10.1126\/scitranslmed.3004186","article-title":"An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity","volume":"4","author":"Ottoboni","year":"2012","journal-title":"Sci Transl Med"},{"doi-asserted-by":"crossref","unstructured":"Gandhi R, Healy B, Gholipour T, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013;73:729\u2013740.","key":"10.1007\/s13311-016-0486-7_bib99","DOI":"10.1002\/ana.23880"},{"key":"10.1007\/s13311-016-0486-7_bib100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12031-014-0476-3","article-title":"Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study","volume":"56","author":"Kacperska","year":"2015","journal-title":"J Mol Neurosci"},{"key":"10.1007\/s13311-016-0486-7_bib101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1742-2094-8-127","article-title":"Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis","volume":"8","author":"Weinstock-Guttman","year":"2011","journal-title":"J Neuroinflamm"},{"key":"10.1007\/s13311-016-0486-7_bib102","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1034\/j.1600-0404.2002.01334.x","article-title":"Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis","volume":"106","author":"Giubilei","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-016-0486-7_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/1744666X.2015.991315","article-title":"Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future","volume":"11","author":"Itay","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"unstructured":"Lovelace, M.D., et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases, Neuropharmacology 2016 Mar 16 [Epub ahead of print].","key":"10.1007\/s13311-016-0486-7_bib104"},{"key":"10.1007\/s13311-016-0486-7_bib105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fimmu.2016.00246","article-title":"current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis","volume":"7","author":"Lovelace","year":"2016","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-016-0486-7_bib106","doi-asserted-by":"crossref","first-page":"e0130715","DOI":"10.1371\/journal.pone.0130715","article-title":"Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing- remitting multiple sclerosis","volume":"10","author":"Mancuso","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-016-0486-7_bib107","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","article-title":"Vitamin D as an early predictor of multiple sclerosis activity and progression","volume":"71","author":"Ascherio","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib108","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ene.12844","article-title":"Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection","volume":"23","author":"Mowry","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib109","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(10)70103-4","article-title":"Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis","volume":"9","author":"Polman","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib110","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/archneurol.2011.65","article-title":"Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis","volume":"68","author":"Buck","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib111","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajhg.2008.07.006","article-title":"HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-\u03b2 therapy in multiple sclerosis","volume":"83","author":"Hoffmann","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-016-0486-7_bib112","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1352458513503597","article-title":"Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development","volume":"20","author":"Hegen","year":"2014","journal-title":"Mult Scler"},{"doi-asserted-by":"crossref","unstructured":"Gibbs E, Karim M E, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated patients with transient versus sustained NAbs. Clin Immunol 2014;157:91\u2013101.","key":"10.1007\/s13311-016-0486-7_bib113","DOI":"10.1016\/j.clim.2014.12.005"},{"key":"10.1007\/s13311-016-0486-7_bib114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2008.02.008","article-title":"Interleukin-17 in transverse myelitis and multiple sclerosis","volume":"196","author":"Graber","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0486-7_bib115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135245859900500206","article-title":"Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis","volume":"5","author":"Matusevicius","year":"1999","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib116","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","article-title":"T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat Med"},{"key":"10.1007\/s13311-016-0486-7_bib117","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jamaneurol.2013.192","article-title":"Interleukin 17F level and interferon \u03b2 response in patients with multiple sclerosis","volume":"70","author":"Hartung","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib118","doi-asserted-by":"crossref","first-page":"16087","DOI":"10.3390\/ijms140816087","article-title":"MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients","volume":"14","author":"Hecker","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1007\/s13311-016-0486-7_bib119","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s11064-014-1386-z","article-title":"Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs","volume":"39","author":"Liu","year":"2014","journal-title":"Neurochem Res"},{"key":"10.1007\/s13311-016-0486-7_bib120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1755-8794-7-26","article-title":"Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-\u03b2","volume":"7","author":"De Felice","year":"2014","journal-title":"BMC Med Genomics"},{"key":"10.1007\/s13311-016-0486-7_bib121","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1352458512460604","article-title":"Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis","volume":"19","author":"Vennegoor","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib122","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/1352458512462920","article-title":"Characterization of anti-natalizumab antibodies in multiple sclerosis patients","volume":"19","author":"Lundkvist","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib123","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrneurol.2015.173","article-title":"Body fluid biomarkers for multiple sclerosis-the long road to clinical application","volume":"11","author":"Teunissen","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib124","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1043-4666(03)00094-2","article-title":"Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes","volume":"24","author":"Ehrlich","year":"2003","journal-title":"Cytokine"},{"key":"10.1007\/s13311-016-0486-7_bib125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.immuni.2004.11.008","article-title":"TRAIL-R as a negative regulator of innate immune cell responses","volume":"21","author":"Diehl","year":"2004","journal-title":"Immunity"},{"key":"10.1007\/s13311-016-0486-7_bib126","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.4049\/jimmunol.168.10.4881","article-title":"Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells","volume":"168","author":"Lunemann","year":"2002","journal-title":"J Immunol"},{"doi-asserted-by":"crossref","unstructured":"Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001;166:1314\u20131319.","key":"10.1007\/s13311-016-0486-7_bib127","DOI":"10.4049\/jimmunol.166.2.1314"},{"key":"10.1007\/s13311-016-0486-7_bib128","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(03)13641-0","article-title":"TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis","volume":"361","author":"Wandinger","year":"2003","journal-title":"Lancet"},{"key":"10.1007\/s13311-016-0486-7_bib129","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00702-004-0225-9","article-title":"Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients","volume":"112","author":"Bartosik-Psujek","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1007\/s13311-016-0486-7_bib130","doi-asserted-by":"crossref","first-page":"e0143393","DOI":"10.1371\/journal.pone.0143393","article-title":"Changes in blood B cell activating factor (BAFF) levels in multiple sclerosis: a sign of treatment outcome","volume":"10","author":"Kannel","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-016-0486-7_bib131","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-b increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity","volume":"131","author":"Krumbholz","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-016-0486-7_bib132","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"doi-asserted-by":"crossref","unstructured":"Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies. Neurology 2007;69:1391\u20131403.","key":"10.1007\/s13311-016-0486-7_bib133","DOI":"10.1212\/01.wnl.0000277457.17420.b5"},{"key":"10.1007\/s13311-016-0486-7_bib134","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0486-7_bib135","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in Natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib136","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002314","article-title":"CD62L is not a reliable biomarker for predicting PML risk in Natalizumab-treated R-MS patients","volume":"86","author":"Lieberman","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0486-7_bib137","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and L-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-016-0486-7_bib138","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult Scler"},{"doi-asserted-by":"crossref","unstructured":"Gnanapavan S, Hegen H, Khalil M, et al. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 2014;83:1210\u20131216.","key":"10.1007\/s13311-016-0486-7_bib139","DOI":"10.1212\/WNL.0000000000000809"},{"key":"10.1007\/s13311-016-0486-7_bib140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","article-title":"Biobanking of CSF: international standardization to optimize biomarker development","volume":"47","author":"Teunissen","year":"2014","journal-title":"Clin Biochem"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0486-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0486-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0486-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:08:14Z","timestamp":1761808094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923015192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1878747923015192"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0486-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0486-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}